Evidence map›Paper›PMID 32065223›Full record

ArticleBrain : a journal of neurology2020

Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.

Edward N Wilson, Michelle S Swarovski, Patricia Linortner, Marian Shahid, Abigail J Zuckerman, Qian Wang, Divya Channappa, Paras S Minhas, Siddhita D Mhatre, Edward D Plowey and 8 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain : a journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01720810 (Pacific Northwest Udall Center), which is not on this map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01720810 unknown statusnot on this map

Pacific Northwest Udall Center (PANUC) Clinical Core

TypeobservationalSponsorUniversity of WashingtonRan2010 to 2025Enrolled2,000ConditionsParkinson Disease, Cognitive Impairment
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Integration of TSPO PET and fluid biomarkers to assess neuroinflammation in Parkinson's disease.European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Effects of α-synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. TREM2-driven peripheral macrophage regulation in inflammatory diseases: implications extending beyond neurological disorders.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Edward N WilsonNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Michelle S SwarovskiNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Patricia LinortnerNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Marian ShahidNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Abigail J ZuckermanNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Qian WangNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Divya ChannappaNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Paras S MinhasNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Siddhita D MhatreNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Edward D PloweyPathology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Joseph F QuinnNeurology, Oregon Health and Sciences University, Portland, OR, USA.
Cyrus P ZabetianVA Puget Sound Health Care System, Seattle, WA, USA.
Lu TianBiomedical Data Science and Statistics, Stanford University, Stanford, CA, USA.
Frank M LongoNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Brenna CholertonPathology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Thomas J MontinePathology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Kathleen L PostonNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Katrin I AndreassonNeurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Stanford University · USOregon Health & Science University · USUniversity of Washington · US

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI Victor Henderson · 2020 to 2026
$29.0M
Udall Center Director's meeting poster awardP50NS062684 · NINDS · UNIVERSITY OF WASHINGTON · PI MONTINE, THOMAS J · 2009 to 2020
$18.3M
Working Memory in Parkinson Disease: A Cognitive & Systems Neuroscience ApproachP50AG047366 · NIA · STANFORD UNIVERSITY · PI HENDERSON, VICTOR · 2015 to 2019
$7.9M
The impact of early Tau pathology on cognitive progression and neuropsychiatric symptoms in Parkinson's diseaseR01NS115114 · NINDS · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I., POSTON, KATHLEEN LOMBARD · 2019 to 2023
$4.2M
The role of TREM1 signaling in the development of Alzheimer’s diseaseRF1AG053001 · NIA · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2016 to 2016
$2.0M
Basal Ganglia Modulation of Cognitive Systems in Parkinson's diseaseK23NS075097 · NINDS · STANFORD UNIVERSITY · PI POSTON, KATHLEEN LOMBARD · 2011 to 2015
$936k
NCATS NIH HHS UL1 TR002369NIA NIH HHS P30 AG066515NIA NIH HHS P50 AG047366NIA NIH HHS RF1 AG053001NIA NIH HHS U24 AG021886NINDS NIH HHS K23 NS075097NINDS NIH HHS P50 NS062684NINDS NIH HHS R01 NS115114
6 · The paper itself

Abstract

Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease and affects 1% of the population above 60 years old. Although Parkinson's disease commonly manifests with motor symptoms, a majority of patients with Parkinson's disease subsequently develop cognitive impairment, which often progresses to dementia, a major cause of morbidity and disability. Parkinson's disease is characterized by α-synuclein accumulation that frequently associates with amyloid-β and tau fibrils, the hallmarks of Alzheimer's disease neuropathological changes; this co-occurrence suggests that onset of cognitive decline in Parkinson's disease may be associated with appearance of pathological amyloid-β and/or tau. Recent studies have highlighted the appearance of the soluble form of the triggering receptor expressed on myeloid cells 2 (sTREM2) receptor in CSF during development of Alzheimer's disease. Given the known association of microglial activation with advancing Parkinson's disease, we investigated whether CSF and/or plasma sTREM2 differed between CSF biomarker-defined Parkinson's disease participant subgroups. In this cross-sectional study, we examined 165 participants consisting of 17 cognitively normal elderly subjects, 45 patients with Parkinson's disease with no cognitive impairment, 86 with mild cognitive impairment, and 17 with dementia. Stratification of subjects by CSF amyloid-β and tau levels revealed that CSF sTREM2 concentrations were elevated in Parkinson's disease subgroups with a positive tau CSF biomarker signature, but not in Parkinson's disease subgroups with a positive CSF amyloid-β biomarker signature. These findings indicate that CSF sTREM2 could serve as a surrogate immune biomarker of neuronal injury in Parkinson's disease.

Indexed as

AgedAmyloid beta-PeptidesBiomarkersCognitive DysfunctionCross-Sectional StudiesDementiaFemaleHumansMaleMembrane GlycoproteinsMiddle AgedParkinson DiseaseReceptors, Immunologictau ProteinsAmyloid beta-PeptidesBiomarkersMembrane GlycoproteinsReceptors, Immunologictau ProteinsTREM2 protein, humanbiomarkercerebrospinal fluidParkinson’s diseasetauTREM2

Identifiers

PMID32065223
PMCPMC7089668
OpenAlexW3006954961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.